Current Oncology Reports

, Volume 2, Issue 2, pp 163–171

Hodgkin’s disease: Prognostic factors and short-course regimens

  • Nancy L. Bartlett
  • Sophia M. Arackal
Article

DOI: 10.1007/s11912-000-0089-6

Cite this article as:
Bartlett, N.L. & Arackal, S.M. Curr Oncol Rep (2000) 2: 163. doi:10.1007/s11912-000-0089-6
  • 23 Downloads

Abstract

Both topics discussed in this review, prognostic factors and short-course regimens for Hodgkin’s disease, have been the focus of recent research with the goal of developing tools and treatments that will result in the highest cure rates with the least long-term sequelae. A new “prognostic score” for advanced-stage Hodgkin’s disease and several potential prognostic factors, including soluble CD30, soluble interleukin-2 receptor, activated cytotoxic T-lymphocytes, and Epstein-Barr virus, are discussed. Preliminary reports of short-course chemotherapy regimens with and without radiotherapy for all stages of Hodgkin’s disease are summarized.

Copyright information

© Current Science Inc 2000

Authors and Affiliations

  • Nancy L. Bartlett
    • 1
  • Sophia M. Arackal
    • 1
  1. 1.Division of Medical OncologyWashington University School of MedicineSt. LouisUSA